Drug intelligence / Profile preview

IMC-4011

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Cell Therapies
Administration: Intravenous

Overview

IMC-4011 is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy developed by ImmuneCyte Life Sciences using its proprietary AutoTIL platform. The therapy involves the isolation of T cells that have naturally migrated into a patient's tumor, followed by their ex vivo activation and expansion to large numbers before re-infusion into the patient. This approach aims to leverage the natural diversity of the patient's own immune system to recognize and eliminate metastatic breast cancer cells. IMC-4011 is currently in the preclinical and pilot phase of development.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on IMC-4011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-4011.

Explore the full profile